ArticleOncoimmunology2016

ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.

Maria Raffaella Zocchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.